Tendon-Homing TGFB1 Latency Mimetic
A tendon-ECM-anchored peptide that locally dampens TGFB1 to steer repair away from fibrosis without systemic immunosuppression.
recovery antagonist pocket: ppi · ▲ 0 · platform draft · 2026-05-02 12:35
🎁 Free tier: 3 design runs / 24h per IP. Each run
produces 4 candidates with full Compounding Lab Spec Sheets — no
signup needed.
Have an API key?
Target structure — TGFB1
AlphaFold v6 · drag to rotate · scroll to zoom · UniProt P01137
Desired effect
Selectively reduces active TGFB1 signaling at injured tendon and ligament sites, shifting healing from scar deposition toward organized collagen-I remodeling. Spares systemic TGFB1 tone, preserving immune homeostasis.
Mechanism rationale
The peptide mimics the LAP-prodomain shoulder that masks mature TGFB1, blocking the integrin-mediated activation step rather than the cytokine itself. A fused collagen-binding domain anchors it to exposed tendon ECM at the injury site, creating a local pharmacology gradient. This converts a notoriously pleiotropic cytokine into a tractable, geography-restricted target.
Novelty basis
No commercialized peptide combines latency-mimetic TGFB1 antagonism with collagen-tethered tissue retention for musculoskeletal recovery.
Strategic value
Buyer profile is mid-cap orthobiologics and sports-medicine players (Smith+Nephew, Stryker Mako biologics, Vericel) plus tendinopathy-focused biotech that have struggled with systemic TGFB inhibitors' safety ceilings. TAM spans rotator cuff repair augmentation, Achilles tendinopathy, and post-ACL reconstruction adjuvant — a >$4B addressable surgical-adjuvant and injectable market. GTM angle is a device-drug combination paired with surgical scaffolds, where local retention data becomes the defensible IP wedge and regulatory de-risking story versus systemic anti-fibrotics.
Design parameters
| Primary target | TGFB1 — P01137 |
|---|---|
| Secondary targets | — |
| Binding mode | antagonist |
| Pocket mode | ppi |
| Modality hint | 14-18 aa bicyclic peptide with two disulfide-stapled loops, N-terminal collagen-binding decapeptide fusion (CBD-derived), subcutaneous depot or intra-lesional administration |